Deprecated: wp_make_content_images_responsive is deprecated since version 5.5.0! Use wp_filter_content_tags() instead. in /home/eapmmilan2018/public_html/wp-includes/functions.php on line 4860

About EAPM 2018

European Congress on Personalised Medicine, Milan 2018
Education Track

Forward as One: Integrating Innovation into Europe’s Healthcare Systems

More than 1000 Life Sciences thought leaders will convene at the second annual EAPM Congress, to be held at Palazzo Lombardia in Milan this November 26-28.

As it did last year in Belfast, the annual event will bring together key audiences who contribute to the vast programme content and vital knowledge exchange.

Don’t miss the opportunity to join large numbers of industry professionals, government regulators, patients, academia, and exhibitors to drive insights to action.

More than ever this year, a focus will be on the upcoming European Parliament elections and the installation of a new College of Commissioners, tasked with devising and implementing regulatory frameworks in all areas, including certain aspects of health.

More than 700 MEPS will be elected next summer and the Commission will also have a new president as Jean-Claude Juncker steps down.

One of the goals of Congress is to engage politicians and lawmakers in the fast-growing field of personalised medicine, and deliver political asks through our consensus-based process.

Europe needs to grasp the fact that health equals wealth and that investment in research and innovation, alongside laws and rules that are fit-for-purpose and reflect the swiftly changing world of medicine, are vital. Hence our continued interaction with MEPs, Commissioners and Member State health leaders.

EAPM also aims to showcase developments and new ideas at Congress. For example, development of major initiatives in genomics and personalised medicine is a global trend with significant investments being committed, for example by the governments of the US and China.

In Europe the most comprehensive initiatives, encompassing clinical implementation, research and enterprise, are being seen in countries such as the UK (100,000 Genomes Project) and France (Médecine Génomique 2025).

It is important that Europe remains competitive in this field given the resulting health and economic benefits and EAPM’s plans for a Million European Genomes Alliance (MEGA) would be synergistic with the national aims, projects and activity of participating Member States and provide structures and a network that can move research to clinical practice and commercial enterprise, putting these countries at the forefront of personalised medicine globally.

MEGA is part of just one of many tracks to be covered in Milan including innovation, education, modern hospitals, funding, guidelines and more.